Background

Toll-like receptors (TLRs) play a crucial role in host defense, inflammation, and immune response, and significant efforts have gone into development of potent TLR agonists. Adjuvants help antigens elicit an early, high and long-lasting immune response, allowing more robust responses to vaccines and reducing vaccine production costs.

Technology Overview

Highly potent and selective TLR8 and dual TLR7/TLR8 agonists can stimulate human adaptive immune response.

• TLR8 agonist: 5-(4-Aminobutyl)-N4-butyl-6-methylpyrimidine-2,4-diamine dihydrochloride is a novel potent and highly selective TLR8 agonist.
• TLR7/TLR8 agonist: N4-butyl-6-methyl-5-(3-morpholinopropyl) pyrimidine-2,4-diamine is a very potent dual TLR7/TLR8 agonist.

These compounds hold potential as vaccine adjuvants that could augment innate immune response against inflammatory, microbial and/or viral diseases as well as cancer.

In these newly discovered agonists, potency